Chun Loo Gan

Chun Loo Gan

Auto-generated profile, based on publicly available information

Chun Loo Gan

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in European Journal of Cancer
Verified
Journal Article
Open access
CGChun L. Gan
Chun L. Gan
ISIgor Stukalin
Igor Stukalin
DMDaniel Meyers
Daniel Meyers
SDShaan Dudani
Shaan Dudani
HGHeidi A.I. Grosjean
Heidi A.I. Grosjean
DHDaniel Y.C. Heng
Daniel Y.C. Heng
Immuno-oncology (IO)-based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not represented in these trials. We sought to compare the outcomes of trial-ineligible vs. -eligible patients with advanced solid tumours treated with first-line (1L) IO therapy. Using the International Metastatic Renal Cell Carcinoma (RCC) Database Consortium and the Alberta Immunotherapy Database, patients with advanced RCC, non-small-cell lung cancer (NSCLC) or melanoma treated with 1L PD-(L)1 inhibition-based therapy were included. Trial eligibility was retrospectively determined as per commonly used exclusion criteria. The outcomes of interest were overall survival (OS), overall response rate (ORR), treatment duration (TD) and time to next treatment (TTNT). A total of 395 of 1241 (32%) patients were deemed trial-ineligible. The main reasons for ineligibility based on preselected exclusion criteria were Karnofsky performance status 1 (40%, 158 of 395), brain metastases (32%, 126 of 395), haemoglobin < 9 g/dL (16%, 63 of 395) and estimated glomerular filtration rate <40 mL/min (15%, 61 of 395). Between the ineligible vs. eligible groups, the median OS, ORR, median TD and median TTNT were 10.2 vs. 39.7 months (p < 0.01), 36% vs. 47% (p < 0.01), 2.7 vs. 6.9 months (p < 0.01) and 6.0 vs. 16.8 months (p < 0.01), respectively. Subgroup analyses showed statistically significant inferior OS, TD and TTNT for trial-ineligible vs. -eligible patients across all tumour types. Adjusted hazard ratios for death in RCC, NSCLC and melanoma were 1.84 (95% confidence interval [CI] 1.22-2.77), 2.21 (95% CI 1.58-3.11) and 1.82 (95% CI 1.21-2.74), respectively.. Thirty-two percent of real-world patients treated with contemporary 1L IO-based therapies were ineligible for clinical trials. Although one-third of the trial-ineligible patients responded to treatment, the overall trial-ineligible population had inferior outcomes than trial-eligible patients. These data may guide patient counselling and temper expectations of benefit.

18 January 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CGChun Loo Gan
Chun Loo Gan
SDShaan Dudani
Shaan Dudani
CWConnor Wells
Connor Wells
FDFrede Donskov
Frede Donskov
SPSumanta K Pal
Sumanta K Pal
DHDaniel Y. C. Heng
Daniel Y. C. Heng
Background: Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized.Methods: Patients with mRCC treated with cabozantinib between 2011 and 2019 were identified and stratified using the International mRCC Database Consortium (IMDC) risk groups. First‐ (1L), second‐ (2L), third‐ (3L), and fourth‐line (4L) overall response rate (ORR), time to treatment failure (TTF), and overall survival (OS) were analyzed. Dose reduction rates and their association with TTF and OS were determined.Results: A total of 413 patients were identified. The ORRs across 1L to 4L were 32%, 26%, 25%, and 29%, respectively, and the median TTF rates were 8.3, 7.3, 7.0, and 8.0 months, respectively. The median OS (mOS) rates in 1L to 4L were 30.7, 17.8, 12.6, and 14.9 months, respectively. For patients treated with 1L PD(L)1 combination agent (n = 31), 2L cabozantinib had ORR of 22%, median TTF of 5.4 months, and mOS of 17.4 months. About 50% (129/258) of patients required dose reductions. The TTF and mOS were significantly longer for patients who required dose reduction vs. patients who did not, with an adjusted hazard ratio of 0.37 (95% CI 0.202–0.672, p < 0.01) and 0.46 (95% CI 0.215–0.980, p = 0.04), respectively. Limitations include the retrospective study design and the lack of central radiology review.Conclusion: The ORR and TTF of cabozantinib were maintained from the 1L to 4L settings. Dose reductions due to toxicity were associated with improved TTF and OS. Cabozantinib has clinical activity after 1L Immuno‐oncology combination agents.

2 March 2020 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
CGChun Loo Gan
Chun Loo Gan
DHDaniel Y. C. Heng
Daniel Y. C. Heng

2 July 2019 in Oncology
Verified
Journal Article
Closed access
PDF file
CTCrescens Tiu
Crescens Tiu
ZLZoe Loh
Zoe Loh
CGChun Loo Gan
Chun Loo Gan
HGHui K Gan
Hui K Gan
TJThomas John
Thomas John
EHEliza Hawkes
Eliza Hawkes
Introduction: The cancer research community increasingly question the rigidity of eligibility criteria in clinical trials. Common reasons for “screen failure” (RFSF) are well documented; however, their effect on subsequent standard therapy (SST) and outcomes is unclear. Methods: This retrospective study evaluated patients aged ≥18 years with solid malignancy who were listed as ineligible on a screening log between February 2011 and March 2018. Patients screen-failed for biomarker results or incorrect cancer stage/prior treatment profile were excluded. Data were collected from electronic hospital records, including demographics, cancer history, RFSF, subsequent therapy, and outcomes. Results: Overall, 217 patients were eligible. The most common histologies were lung (28%), melanoma, colon, and pancreatic (all 11%); 90% were metastatic. The most common RFSF were rapid disease progression (PD; 16%), performance status (PS) ≥2 (12%), and abnormal liver function tests (aLFT; 12%). After screen failure, 129/217 (59%) had SST; 9 were dose-reduced. Treatment-naïve or phase III trial-ineligible patients were more likely to receive SST than those pre-treated or phase I trial-ineligible (72/104 vs. 52/113, p = 0.0006; 71/109 vs. 15/42, p = 0.00013), respectively. RFSF stabilised/improved in 104/217 (48%); the main RFSF was co-morbidity (19/104). The most common RFSF to deteriorate were rapid PD (27/72), PS ≥2 (20/72), and aLFT with liver metastases (LM; 13/72). Conclusions: RFSF related to organ function rarely deteriorate unless directly involved with underlying malignancy. Most RFSF do not prevent patients from having SST, nor increase dose reductions, especially in treatment-naïve/phase III trial-ineligible patients. Those with RFSF of poor PS, rapid PD, and aLFT from LM are less suitable for SST. Careful broadening of trial eligibility is warranted.

25 November 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
CTC. Tiu
C. Tiu
ZLZ. Loh
Z. Loh
CGC. Gan
C. Gan
JHJ. Hakanson
J. Hakanson
HGH. Gan
H. Gan
EHE. Hawkes
E. Hawkes
Background: Researchers are questioning the rationale for current rigidity of eligibility criteria in cancer clinical trials. In ineligible patients, the effect of RFSF on subsequent standard treatment (SST) is unclear. We review RFSF in a tertiary centre and their impact on SST.

1 September 2020 in Annals of Oncology
Verified
Journal Article
Closed access
CGC.L. Gan
C.L. Gan
ISIgor Stukalin
Igor Stukalin
DMDaniel Meyers
Daniel Meyers
SDS. Dudani
S. Dudani
HGH.A.I. Grosjean
H.A.I. Grosjean
DHD.Y.C. Heng
D.Y.C. Heng